Niagen Bioscience Q1 sales rise 3%, beat estimates

Niagen Bioscience

06/05/2026 21:21

Overview

US NAD+ supplement maker's Q1 net sales rose 3%, beating analyst expectations

Adjusted EPS for Q1 matched analyst consensus

Company repurchased $2.4 mln in shares during the quarter

Outlook

Company sees 2026 net sales rising 10-15% year-over-year, excluding divested segment

Gross margin expected to improve slightly in 2026

General & administrative expense seen up $3-4 mln in 2026

Result Drivers

TRU NIAGEN AND E-COMMERCE - Co said net sales growth was driven by continued growth in Tru Niagen, led by strong e-commerce performance and higher sales through different distribution channels, partially offset by variability in orders from A.S. Watson

GROSS MARGIN IMPROVEMENT - Gross margin rose to 63.5%, reflecting favorable business mix and supply chain efficiencies

DIVESTITURE GAIN - Net income included a $4.8 mln gain from the sale of the Analytical Reference Standards and Services segment

Company press release: ID:nBw29jgFda

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
Beat
$31.47 mln
$30.95 mln (5 Analysts)
Q1 EPS
Meet
$0.07
$0.07 (5 Analysts)
Q1 Net Income
$6.32 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Niagen Bioscience Inc is $12.00, about 149% above its May 5 closing price of $4.82

The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 20 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)